-+ 0.00%
-+ 0.00%
-+ 0.00%

Immuneering says atebimetinib-chemo trial shows 17.3-month median survival in pancreatic cancer

PUBT·05/21/2026 21:02:48
Listen to the news
Immuneering says atebimetinib-chemo trial shows 17.3-month median survival in pancreatic cancer
  • Immuneering reported updated Phase 2a results for atebimetinib with chemotherapy in first-line metastatic pancreatic cancer, with full data slated for an oral presentation at the ASCO Annual Meeting on June 1, 2026.
  • The update pointed to longer survival with manageable tolerability, with severe treatment-related side effects largely attributed to chemotherapy rather than the investigational drug.
  • The readout supports the company’s planned randomized Phase 3 MAPKeeper 301 trial, which is recruiting with a first patient dosing targeted for mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.